Entrada Therapeutics (NASDAQ:TRDA) Price Target Raised to $20.00

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) had its price objective boosted by investment analysts at HC Wainwright from $18.00 to $20.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's target price would indicate a potential upside of 7.18% from the stock's previous close.

Separately, Oppenheimer restated an "outperform" rating and set a $25.00 price target on shares of Entrada Therapeutics in a research note on Monday, August 26th.

Entrada Therapeutics Trading Up 0.2 %

Shares of TRDA traded up $0.04 during mid-day trading on Wednesday, hitting $18.66. The company's stock had a trading volume of 247,621 shares, compared to its average volume of 104,558. The firm has a market capitalization of $694.15 million, a price-to-earnings ratio of 6.30 and a beta of -0.26. The company's 50-day moving average is $16.33 and its 200-day moving average is $15.61. Entrada Therapeutics has a 52-week low of $10.75 and a 52-week high of $19.78.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, topping the consensus estimate of $0.65 by $0.90. Entrada Therapeutics had a return on equity of 35.16% and a net margin of 43.63%. The firm had revenue of $94.69 million during the quarter, compared to analyst estimates of $55.00 million. As a group, sell-side analysts predict that Entrada Therapeutics will post 0.68 earnings per share for the current fiscal year.

Insider Activity at Entrada Therapeutics

In other Entrada Therapeutics news, COO Nathan J. Dowden sold 1,904 shares of the company's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.07, for a total value of $28,693.28. Following the completion of the sale, the chief operating officer now directly owns 125,996 shares in the company, valued at $1,898,759.72. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Entrada Therapeutics news, COO Nathan J. Dowden sold 1,904 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $15.07, for a total transaction of $28,693.28. Following the completion of the transaction, the chief operating officer now owns 125,996 shares of the company's stock, valued at $1,898,759.72. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Natarajan Sethuraman sold 2,642 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $15.09, for a total transaction of $39,867.78. Following the transaction, the insider now directly owns 183,816 shares of the company's stock, valued at $2,773,783.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,187 shares of company stock valued at $155,947. 7.59% of the stock is owned by corporate insiders.

Institutional Trading of Entrada Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Entrada Therapeutics by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company's stock worth $15,288,000 after purchasing an additional 13,742 shares during the period. American Century Companies Inc. grew its holdings in Entrada Therapeutics by 5.1% during the 2nd quarter. American Century Companies Inc. now owns 384,973 shares of the company's stock worth $5,486,000 after acquiring an additional 18,625 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Entrada Therapeutics by 13.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company's stock worth $1,787,000 after acquiring an additional 14,838 shares in the last quarter. Marshall Wace LLP increased its position in shares of Entrada Therapeutics by 27.5% in the 2nd quarter. Marshall Wace LLP now owns 65,943 shares of the company's stock valued at $940,000 after purchasing an additional 14,220 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Entrada Therapeutics by 3.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company's stock valued at $814,000 after purchasing an additional 2,146 shares in the last quarter. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.